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Abstract 
 
Cancer treatment has made significant strides towards the promise of personalized medicine. 
Recent scientific advances have shown that there are numerous genetic deregulations that are 
common in multiple cancer types, raising the possibility of developing drugs targeting those 
deregulations irrespective of the tumour type. Precision cancer medicine was born out of 
accumulated evidence matching targeted agents with these tumour molecular deregulations. At the 
same time, the therapeutic armamentarium is rapidly increasing and the number of new drugs 
(including immune-oncology agents) entering drug development continues to rise. These factors, 
added to strong collaboration with regulatory agencies which have approved novel agents based on 
data obtained from Phase 1/2 trials, have led to unprecedented evolution in the design of early 
stage clinical trials. Currently, we have seen rapid Phase 1 dose escalation trials followed by 
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remarkably large expansion cohorts, and are witnessing the emergence of new trials, such as 
adaptive studies with basket and umbrella designs aimed at optimizing the biomarker-drug co-
development process. Alongside the growing complexity of these clinical trials, new frameworks for 
stronger and faster collaboration between all stakeholders in drug development, including academic 
institutions and frameworks, clinicians, pharma companies and regulatory agencies, have been 
established. In this review article, we describe the main challenges and opportunities that these new 
trial designs may provide for a more efficient drug development process, which may ultimately help 
ensure that precision cancer medicine becomes a reality for patients. 
 
Abbreviations 
 
BOB- Basket of Baskets 
CCE-Cancer Core Europe 
COSMIC - Catalogue of Somatic Mutations in Cancer  
CTC - Circulating tumor cell 
ctDNA - Circulating tumor DNA  
DLT: Dose Limiting Toxicity 
dMMR: defective mismatch repair 
EMA - European Medicines Agency 
FDA - Food and Drug Administration  
ICGC - International Cancer Genome Consortium  
MSI: Microsatellite Instability 
NCI - National Cancer Institute  
NSCLC - Non-small cell lung cancer  
NTKR:  Neurotrophin tropomyosin receptor kinase 
PCM - Precision Cancer Medicine  
TCGA - The Cancer Genome Atlas
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1.- Introduction 
Over recent years much progress has been made in rendering cancer treatments more precise. 
Scientific and technological advances have unmasked numerous genetic deregulations that are 
common across multiple cancer types. These discoveries have led to the development of drugs 
targeting driver gene alterations irrespective of their primary tumour location. We are consequently 
witnessing the ringing in of a new era characterized by considering tumours as genetic diseases as 
opposed to tissue-dependent processes. This is accelerating the pace from molecular aberration 
discovery to the approval of new therapies (Hierro et al., 2017; Hunter DJ., 2016; Dienstmann et al., 
2013a; Dienstmann et al., 2013b). 
 
At the same time, during this last years the arrival of immune therapy to the oncology therapeutic 
armamentarium has marked a ground-breaking milestone for the treatment of cancer patients, and 
the number of immune-oncology agents entering drug development continues to rise (Martin-
Liberal et al., 2017) . These factors, added to the strong collaboration with the regulatory agencies, 
approving novel agents based on data obtained from phase 1/2 trials, have led to an unprecedented 
evolution in the design of early stage clinical trials (Bui and Kummar, 2018). In this regard, the US 
Food and Drug Administration (FDA) has approved 10 anti-cancer drugs matched to companion 
diagnostic biomarkers based on data obtained from non-randomized trials in the last 2 years. This 
evolution is mainly driven by the desire to facilitate patients’ access to drugs with promising activity 
from the early stages of development and is also a consequence of pharmaceutical companies 
striving to obtain rapid regulatory approval of their anti-cancer medicines. 
The traditional drug development track where drugs were evaluated for safety in phase 1, early signs 
of efficacy in phase 2 and finally evaluated against standard therapy in a randomised phase 3 clinical 
trial, has gradually faded out. Currently we are facing rapid phase 1 dose escalation trials followed 
by strikingly large expansion cohorts and the emergence of new trials such as adaptive studies with 
basket and umbrella designs aimed at optimizing the biomarker-drug co-development process. In 
parallel, with the growing complexity of clinical trials, new frameworks for stronger and faster 
collaboration between all stakeholders in drug development including clinicians, pharma companies 
and regulatory agencies, have been established (Weber et al., 2017; Harrington et al., 2017). 
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2.- Precision medicine trials for cancer 
With the development and clinical use of molecularly targeted agents, it became clear that only 
selected patient populations would derive benefit from these therapies. Precision Cancer Medicine 
(PCM) was born out of the accumulated evidence on matching targeted agents with tumour 
molecular aberrations (Dienstmann R et al, 2015, Hoelder et al., 2012).  Those drugs designed to 
interact with a specific target, and especially those using predictive biomarkers, showed the highest 
relative improvement in response rate and survival (Ocana at al., 2013). Current knowledge 
generated from large-scale collaborative sequencing projects such as the Cancer Genome Atlas 
(TCGA) and the International Cancer Genome Consortium (ICGC), in addition to publicly available 
resources such as the cBioPortal for Cancer Genomics and the Catalogue of Somatic Mutations in 
Cancer (COSMIC), have facilitated our understanding of the genetic interpatient tumour 
heterogeneity in multiple cancers subtypes (Dienstmann et al., 2013a)   Most druggable genomic 
aberrations are present only in small to moderate proportions of patients, further emphasizing 
multicentre collaboration in early drug development as critical for successful clinical trial enrolment. 
(Dienstmann R et al, 2015) 
In addition, recent studies have also described striking intra-patient intra-tumour heterogeneity and 
how clonal evolution under treatment pressure may represent major obstacles in PCM, questioning 
the value of a single needle biopsy or surgical excision to accurately capture the complete genomic 
landscape of a patient’s cancer (Hunter, 2016; Bedard et al., 2013). Nevertheless, we believe that 
the described heterogeneity in genomic profiles particularly applies to bystander mutations and that 
true tumour-driving events are usually present in the majority of subclones from the primary tumour 
as well as the metastatic lesions (Yap et al, 2012). Therefore, regimens targeting driver genomic 
alterations with high variant frequencies are expected to provide substantial tumour responses. 
Since clinical responses to targeted agents are consistently abrogated by the development of drug 
resistance, we consider repeated tumour biopsies of progressing lesions and/or characterization of 
circulating markers (tumour cells, tumour DNA) to be a key component of patients’ care, allowing 
the identification of mechanisms of resistance as well as potentially guiding alternative treatment 
options with experimental agents.  
In terms of clinical trials incorporating biomarkers, an essential element that should be factored in is 
the turnaround time for test results, particularly with tumour clinical next-generation sequencing, 
for patients undergoing molecular profiling. This is especially important in the metastatic setting 
when treatment decisions have to be made within a short timeframe.  
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As an alternative to the traditional approach of centralized biomarker analysis prior to evaluating the 
inclusion of a patient in a trial, multiple academic centres have adopted a different strategy 
consisting of local pre-screening at academic institutions while patients are still receiving standard 
treatment for advanced disease. While this approach is time and tissue saving and increases the 
chances of patient recruitment in early clinical trials, the financial burden of pre-screening tests is 
transferred from trial sponsors to health care providers and academic institutions (Dienstmann R et 
al, 2015, Rodon et al., 2012).  
In order to efficiently and dynamically incorporate genomic data and assess the value of matching 
profiled patients whose tumours harbour unique genomic alterations to specific interventions or 
targeted therapies, clinical trials design for cancer diagnostics and therapeutics must take these 
rate-limiting steps into consideration. 
 
2.1.- Adaptive studies 
A clinical study with adaptive design is defined as one that includes planned opportunities to modify 
one or more specified elements of the study design and hypothesis based on data analysis (usually 
intermediate findings) of the study subjects. Research into the accumulated data is carried out 
within the study at specific, prospectively planned time-points, and can be performed in a 
completely blind or a non-blind way. The term prospective refers to the fact that the change was pre 
planned (and the details specified) before the data was examined in a non-blinded manner 
(CHMP/EWP/2459/02, 2007). The final objective of adaptive designs is to learn from the 
accumulated data and apply what has been observed as soon as possible. The modifications to the 
study design that can be planned in the written protocol cover a broad range of possibilities. 
Examples include: study eligibility criteria, proportion of randomization, addition of new treatments, 
and sample size of the study (Gallo et al., 2006). 
Adaptive design trials have been shown to increase the efficiency of traditional clinical trials by 
facilitating the selection of the dose, reducing the number of patients exposed to ineffective or 
potentially toxic doses, aiding the precise calculation of sample size and reducing the duration and 
costs of clinical development. These new designs in early drug development enable the integration 
of pre-clinical data, the incorporation of information beyond the traditional DLT period, findings 
from other trials and emerging safety data; thereby increasing the likelihood of accurately 
determining any benefit of a new treatment and complying more quickly with regulatory 
requirements for efficacy and safety (Harrington et al., 2017). 
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In this regard, the formal reasons for stopping the study in an intermediate analysis could be: (i) 
safety (if one of the interventions involves many adverse events); (ii) efficacy (if it shows efficacy of 
one of the interventions); or (iii) futility (if the objectives are not achievable or unlikely to be 
achieved with a statistical significance). On the other hand, the sponsor may have the option of 
responding to intermediate data on safety and efficacy in various ways, such as narrowing the trial 
approach (example: elimination of one or more treatment groups based on futility criteria) or 
increasing the number of participants (example: if the data available at the time of the review does 
not allow for a clear decision between utility and futility, the enrolment of participants might be 
extended to one or more treatment groups beyond the initially intended sample). Cost reduction is 
achieved through the early identification of successful groups, leaving unnecessary treatment groups 
out of the equation or determining effective dosing regimens more quickly (Menis et al., 2014; Korn 
and Freidlin, 2017.) 
Well-known examples of adaptive measures in clinical trials include early stopping rules in the 
instances of a lack of efficacy or unacceptable toxicity and altering doses or schedules of drugs in 
order to improve the benefit-toxicity profile. More recently, novel adaptation strategies have been 
proposed. In the adaptive accrual design, after the initial “learning phase”, the ratio of patients 
randomly assigned to the experimental arm versus the control arm changes from the standard 1:1 to 
increase the proportion of patients randomized to the arm that is performing better, which 
augments the statistical power to detect a relevant magnitude of clinical benefit.  
The BATTLE-2 study (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer 
Elimination 2), for example, is a biomarker-based and biopsy-mandatory prospective trial to guide 
treatment of heavily pre-treated metastatic NSCLC patients (NCT01248247). In the “adaptive phase”, 
randomization to different drugs or combinations is weighted based on mutation profile results 
generated in real time. A similar framework can be applied to studies assessing the predictive value 
of gene expression signatures. Instead of using a fixed model - built on the training data only - 
adaptive strategies use the information on patients enrolled earlier in the testing set to continuously 
update the model and refine accrual throughout the entire study (Dienstmann R et al, 2015, Xiao et 
al., 2014).  
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Adaptive models increase the weights of good predictors and decrease the weights of unstable 
predictors, improving the overall performance of the classifier and selecting the “best” matched 
therapy to current patients’ characteristics. These algorithms may facilitate the use of molecular 
signatures to predict the clinical outcomes of patients in prospective clinical studies.  
In the realm of precision medicine, enrichment trials with adaptive designs where predictive 
algorithms incorporating prior knowledge (based on in silico models of drug sensitivity, ex vivo 
experiments, preclinical or early clinical data) are used to guide the best matched targeted therapy 
in particular settings have been envisioned. This may be useful when multiple druggable alterations 
are identified in a patient’s tumour sample and more than one agent is available for testing; and 
when one driver genomic event is identified, and the investigator has to select among various drugs 
with overlapping mechanisms of action (targeting the same driver event) but with different 
potency/activity according to coexisting genomic alterations. These “machine-learning predictive 
models” can complement molecular tumour boards efforts to identify the “best guess” (Pemovska et 
al., 2013). 
Both, the European Medicines Agency (EMA) and the FDA have already recognized the validity of 
clinical trials with adaptive characteristics as a viable alternative strategy for both pivotal and early 
trials in the regulatory environment of pharmacological development (9). However, regulatory 
agencies are still reluctant in some cases to consider adaptive designs, as the results can be more 
difficult to interpret. One of the main concerns is the control of the type I error rate as well as the 
fact that adaptive measures may introduce bias (Menis et al., 2014; Bauer et al., 2016). Another 
important challenge of this type of studies is providing the information to the patient in a sufficiently 
precise but at the same time comprehensible way. These studies have complex designs, with several 
cohorts and one or several drugs under investigation. Above all, they can vary overtime which 
increases the uncertainty of the trial design and makes it very difficult to explain to the patient. To 
address this challenge, the trials will have different informed consents depending on the specific 
cohort( Korn and Freidlin, 2017.  
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2.2.- Umbrella protocols 
An umbrella trial is a master protocol for which the patient's eligibility is defined by the presence of 
a tumour type that is sub-stratified according to specific molecular alterations matched to different 
anti-cancer therapies (Woodcock et al., 2017).  
Several Umbrella Protocols in which patients were stratified by potential molecular biomarker and 
assigned to matched therapies, were initiated to evaluate the role of Precision Medicine in certain 
tumour types, such as the I-SPY1/2 (Carey and Winer, 2016; Das and Lo, 2017)  in breast cancer, the 
BATTLE 1/2 (Papadimitrakopoulou et al., 2016) in lung cancer, or the FOCUS-4 Adams et al., 2018) 
and MoTriColor  in colorectal cancer (H2020 grant agreement no. 635342). Some studies tested or 
are testing this framework across multiple solid tumours, such as MOSCATO (Massard et al., 2017)  
or NCI-MATCH trials (Mullard, 2015).  
In some studies, such as MOSCATO, patients had limited access to a set of matched therapies, while 
others including I-SPY and NCI-MATCH have overcome this limitation by building networks and 
efficient partnerships with the pharmaceutical industry. Despite strong collaborations, some studies 
have been limited by the suboptimal biomarkers and matched drugs used including the BATTLE or 
the SHIVA trials (Adams et al., 2018; Le Tourneau et al., 2015 ). To deal with thus limitation, the I-
SPY1/2 studies and the NCI-MATCH have successfully implemented adaptive designs allowing the 
addition of new arms as new knowledge became publicly available. Most studies have remained 
fixed to their initial treatment algorithms, sometimes outdated at the time of study closure. Also, 
there was no flexibility to integrate new technologies that might be of interest, RNA-based 
multiplexed assays for the detection of fusion events.  
The I-SPY1/2 studies and the NCI-MATCH have successfully implemented flexible designs allowing 
for the addition of new arms as new data becomes publicly available; while others have remained 
fixed to their initial treatment algorithms that could be outdated by the time they close. In most of 
these studies, tumour molecular characterization is based on DNA analysis-platforms, with little 
flexibility to integrate other technologies that might be of interest, such as RNA-based multiplexed 
assays for the detection of fusion events and gene signatures that define unique portraits of 
tumours. An example of the latest approach is the MoTriColor EU H2020 funded project, a set of 
molecularly guided trials with specific treatment strategies in patients with advanced newly 
molecular defined subtypes of colorectal (gene signatures-based) cancer (H2020 grant agreement 
no. 635342). 
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2.3.- Basket trials 
Basket trials include patients with different tumour types with a common molecular alteration who 
are treated with the same matched therapy (Carey and Winer, 2016; Redig and Jänne., 2015 ). They 
constitute a histology-agnostic approach to evaluate targeted agents in molecularly selected 
populations and can provide access to experimental therapies for patients across a wide range of 
tumour types, potentially including those rare tumours that would have not been studied in other 
clinical trials (Billingham et al., 2016). The first basket study design evaluated the efficacy of 
vemurafenib in solid tumours or haematological malignancies harbouring BRAFV600 mutations 
(NCT0152497). This design evidenced the activity of vemurafenib in BRAF V600E mutant NSCLC, and 
also showed activity in other tumour types such as ovarian cancer and certain central nervous 
system cancers (Hyman et al., 2015).   
Limitations of this approach include: (i) the assumption that the same mutation might have the same 
impact regardless of histology; (ii) the presence of variants of unknown significance whose function 
has not previously been evaluated; (iii) an inherent focus on one single alteration (when nowadays 
multi-marker analysis is standard); and (iv) without a control arm it can be difficult to differentiate 
predictive from prognostic value of a biomarker. One important caveat is the possibility of an 
insufficient representation of patients with certain tumour types that harbour the alteration of 
interest, leading to false-negative conclusions. Therefore, basket trials should be stratified by 
histology, taking into consideration the reported frequencies of the genomic event (Bedard et al., 
2013). This strategy may be even adapted to increase enrolment of patients with tumour types that 
demonstrate early signals of anti-tumour activity while excluding those lacking preliminary response. 
Furthermore, additional cohorts with different tumour types can be created, and patients with 
related molecular aberrations can also be enrolled – those with newly identified fusion genes known 
to activate the pathway and sensitize to the agent under investigation similarly to gene copy number 
alterations or mutations, for example (Dienstmann R et al, 2015). Moreover, if other driver 
molecular alterations coexist, patients could be offered combination regimens targeting more than 
one single alteration. 
The rarity of certain tumour-biomarker combinations makes it impossible to conduct randomised 
trials. As a consequence, basket trials have increasingly been used as a potential means of providing 
the clinical data necessary to support such a shift in treatment approach.  On May 23, 2017 the FDA 
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granted the accelerated approval of pembrolizumab for the treatment of adult and paediatric 
patients with unresectable or metastatic refractory tumours harbouring microsatellite 
instability/defective mismatch repair (MSI-H/dMMR). The first FDA tissue-agnostic approval became 
a reality, based on the tumour response rate and the durability of response seen in 149 patients 
with MSI-H/dMMR tumours across the five uncontrolled, open-label, single-arm trials (Diaz et al., 
2017). Response rates were comparable across tumours, with 36% in colorectal cancer versus 46% in 
14 other cancer types.   
Following the approval of pembrolizumab, another very recent milestone has revolutionized the 
drug development field, with the approval of larotrectinib on November 2018 for the treatment of 
adult and paediatric neurotrophin tropomyosin receptor kinase (NTRK) rearranged tumours. 
Patients with NTRK fusion positive tumours were enrolled into the adult phase 1, the paediatric 
SCOUT phase 1/2, or the NAVIGATE “basket” phase 2 trials evaluating larotrectinib, a first-in-class 
pan-TRK inhibitor (Drillon et al., 2018). The expanded 122-patient integrated dataset showed an 
overall response rate of 81% (95% CI, 72-88). Remarkably, 84% of the responding patients and 73% 
of all patients remained on larotrectinib or underwent surgery with curative intent. Strikingly, 
larotrectinib demonstrated clinical benefit regardless of tumour type, NTRK gene, fusion partner or 
age of the patient (Lassen et al., 2018). Both of these approvals inaugurate a new area, with multiple 
new agents, such as RET inhibitors, following this new path (Subbiah et al., 2018; Garber, 2018).  
 
3.- The Basket of Baskets study: an example of EU collaborative basket framework with multi-
modular design 
 
The Basket of Baskets (BoB) study is the spearhead Program of the Cancer Core Europe (CCE) 
(Eggermont et al., 2014). Its overall goal is to evaluate the antitumor activity of matched therapies in 
small CCE patient populations molecularly-selected using a novel study design in an international 
multicentre (basket) approach. 
The study consists of two parts: (i) I-Profiler will allow the molecular characterization of tumours 
from patients with metastatic or recurrent solid tumours using a new profiling tool and select the 
most suitable treatment for these patients; and (ii) I-Basket is a multimodular basket trial, with 
different cohorts for genomically selected populations. Pharmaceutical companies will sponsor some 
of the specific treatment cohorts and will also benefit from the established collaboration and 
profiling to perform Pharma-sponsored trials (Figure 1) (Calvo et al., 2018). 
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The BoB study is testing therapies in multiple disease settings/genetic contexts, encompassed by the 
development of companion diagnostics based on specific biomarkers in these genetic contexts, 
including ctDNA analysis as a way to select patients for any of the tested drugs and thus increase the 
efficacy of treatments. A broader genetic analysis also facilitates the testing of the feasibility and 
value of whole exome sequencing (WES) in a clinical context, as well as the development of a 
database for the stratification of other patient populations that could benefit for drug repurposing. 
 
The CCE setting has aligned seven academic sites with state-of-the-art platforms for molecular 
patient selection, a critical mass of patients and a unique infrastructure including bioinformatics and 
translational research capabilities that can support clinical trials in small patient populations. The 
framework collaboration integrates standardized pre-screening methods (including a 350-genes 
panel in tier 1) and common standard operating procedures (SOPs), contracts and budgets. Its 
design allows both the development of sponsor-initiated trials and modular investigator-initiated 
trials, providing flexibility for adding new arms with different molecular alterations. The consortium 
comprises investigators and industrial partners as a collaborative initiative to explore the anti-
tumour activity of multiple drugs in many different genetic contexts, provider flexible tools for 
tumour analysis (from discovery to market), study implementation (from pilot studies to registration 
of new indications – repurposing) and translational research (mechanisms of resistance, 
heterogeneity). The design allows a cost-effective use of the shared platforms and aims at 
dramatically accelerating new indications (repurposing) of the tested targeted therapies by 
providing clinical evidence of activity and validated companion diagnostics for use in confirmatory 
trials. 
 
BoB seeks to accomplish ambitious advances: (i) Advance logistics of genomically-oriented clinical 
trials through a structure that incorporates novel concepts and approaches and facilitates 
cooperation between academic sites, diagnostic companies and pharma; and (ii) Implement  this 
innovative clinical research strategy for the development of targeted therapies in numerous 
molecular alteration settings, driven by tight connectivity between experts in genetics, translational 
science and clinical research with the profiling tools to assess the clinical benefit of those targeted 
therapies. This will help bridge the existing gap between scientific discovery in basic and 
translational research and its application in a clinical research setting. 
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Conclusions 
In this review we present some of the complexities and recent advances of research in precision 
medicine. Concepts such as Phase 1 expansion cohorts replacing Phase 2 testing, regulatory 
approvals based on non-randomized trials and tumour agnostic approvals are now here to stay in 
the field of drug development. Challenges include technical limitations of molecular tests, logistical 
issues for patient accrual in clinical trials and critical, unsolved regulatory issues. Importantly, 
knowledge in genomics is steps ahead of our ability to therapeutically target tumours given that 
many mutations identified by sequencing are either linked to unapproved drugs or are not druggable 
by currently available therapies.  
Genetic heterogeneity at intra-tumour and inter-patient levels and clonal evolution of tumours over 
time remain among the major obstacles for precision medicine to materialize. Given the potential of 
genomic characterization of circulating tumour cells (CTCs) and DNA (ctDNA), we expect that these 
circulating blood biomarkers will be important for monitoring the emergence of treatment-resistant 
clones under selective pressures and providing an efficient model of individualized therapy. Clinical 
trial strategies such as platform studies with adaptive designs, innovative endpoints and 
collaborative frameworks to interrogate the efficacy of drugs will be key to advancing precision 
medicine. 
 
Acknowledgements 
 
The authors want to acknowledge support by: European Community’s H2020 grant agreement no. 
635342 MoTriColor (JT, RD and AP); the Cellex Foundation (all authors) and Cancer Core Europe (all 
authors). We also thank the support received from the Welfare Projects Division of the “La Caixa” 
Foundation to the Molecular Therapeutics Research Unit (UITM). 
 
Authors’ contribution:  
All authors contributed to the writing and review of this article. 
 
 
Declaration of Interests 
 
EG declares Advisory role for Roche, Janssen, NeoMed Therapeutics, Boehringer and Ellypses 
Pharma; Speaker’s fee from MSD and Direct Research Funding from Novartis.  
A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
RD declares Advisory role for Roche and Novartis; Speaker’s fee from Roche, Symphogen, Ipsen, 
Amgen and Sanofi and Direct Research Funding from Merck. 
AP has no conflicts to declare. 
IB declares Advisory role for Orion Pharma; Speaker’s fee from BMS, AstraZeneca and Merck Serono; 
and Financial Support for clinical trials or contracted research for AstraZeneca, BMS, Celgene, 
Gliknik, GSK, Janssen, KURA, MSD, Novartis, Orion Pharma and Pfizer. 
JR declares Advisory role for Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, 
Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals 
Inc, Pfizer, Roche Pharmaceuticals, and Ellipses Pharma; and Direct Research Funding from Bayer 
and Novartis; and serving as investigator in clinical trials with Spectrum Pharmaceuticals, Tocagen, 
Symphogen, BioAtla, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, Glaxo Smith Kline 
and Ipsen. 
JT declares Advisory role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, 
Chugai, Genentech, Inc., Genmab A/S,  Halozyme, Imugene Limited, Inflection Biosciences Limited, 
Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, 
Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La 
Roche Ltd, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, 
Foundation Medicine, HalioDX SAS and Roche Diagnostics; and Financial Support for clinical trials or 
contracted research for Agendia BV, Amgen, Debiopharm, Janssen-Cilag, Mologen AG, Novartis, 
Pharma Mar, Roche, Servier and Symphogen. 
 
  
References 
Adams, R., Brown, E., Brown, L., et al., 2018. Inhibition of EGFR, HER2, and HER3 signalling in 
patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 
randomised trial. Lancet Gastroenterol Hepatol 3(3), 162-171.  
 
Bauer, P., Bretz, F., Dragalin, V., Konig, F.,Wassmer, G., 2016. Twenty-five years of confirmatory 
adaptive designs: opportunities and pitfalls. Stat Med 35(3), 325-47. 
 
Bedard, PL., Hansen, AR., Ratain, MJ., Siu, LL., 2013. Tumour heterogeneity in the clinic. Nature 
501(7467), 355-364. 
 
A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
Billingham, L., Malottki, K., Steven, N., 2016. Research methods to change clinical practice for 
patients with rare cancers. Lancet Oncol 17(2), e70–e80. 
 
Bui, NQ., Kummar, S., 2018. Evolution of early phase clinical trials in oncology. Journal of Molecular 
Medicine 96, 31–38. 
 
Calvo, F., Apolone, G., Baumann, M., 2018. Cancer Core Europe: A European cancer research alliance 
realizing a research infrastructure with critical mass and programmatic approach to cure cancer in 
the 21st century. Eur J Cancer 103, 155-159. 
 
Carey, LA., Winer, EP., 2016. I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment. N 
Engl J Med 375(1), 83-84.  
 
Das, S., Lo, AW., 2017. Re-inventing drug development: A case study of the I-SPY 2 breast cancer 
clinical trials program. Contemp Clin Trials 62, 168-174. 
 
Diaz, L., Marabelle, A., Kim, TW., Geva, R., Van Cutsem, E., André, T., et al., 2017. Efficacy of 
pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high 
cancers. Ann Oncol 28. 
 
Dienstmann, R., Rodon, J., Barretina, J., et al., 2013a. Genomic medicine frontier in human solid 
tumors: prospects and challenges. J Clin Oncol 31, 1874-1884. 
 
Dienstmann, R., Rodon, J., Tabernero, J., 2013b. Biomarker-driven patient selection for early clinical 
trials. Curr Opin Oncol 25, 305-312.  
 
Dienstmann R,Rodon J,Tabernero. 2015.   Optimal design of trials to demonstrate the utility of 
genomically‐guided therapy: Putting Precision Cancer Medicine to the test.  Mol 
Oncol.May;9(5):940-50 
 
Drilon, A., Laetsch, TW., Kummar, S., DuBois, SG., Lassen, UN., Demetri, GD., et al., 2018. Efficacy of 
Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378(8), 731-739. 
 
A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
Eggermont, AM., Caldas, C., Ringborg, U., et al., 2014. Cancer Core Europe: a consortium to address 
the cancer care-cancer research continuum challenge. Eur J Cancer 50(16), 2745-2746. 
 
European Medicines Agency, 2007. Reflection Paper on Methodological Issues in Confirmatory 
Clinical Trials Planned with an Adaptive Design. CHMP/EWP/2459/02  
 
Gallo, P., Chuang-Stein, C., Dragalin, V., et al., 2006. Adaptive Designs in Clinical Drug Development—
An Executive Summary of the PhRMA Working Group. J Biopharm Stat 16(3), 275-283. 
 
Harrington, JA., Hernandez-Guerrero, TC., Basu, B., 2017. Early Phase Clinical Trial Designs e State of 
Play and Adapting for the Future. Clinical Oncology (R Coll Radiol) 29, 770-777. 
 
Hierro, C., Azaro, A., Argilés, G., Elez, E., Gómez, P., Carles, J., Rodon, J., 2017. Unveiling changes in 
the landscape of patient populations in cancer early drug development. Oncotarget 8(8), 14158-
14172 
 
Hoelder, S., Clarke, P.A., Workman, P., 2012. Discovery of small molecule cancer drugs: successes, 
challenges and opportunities. Mol Oncol 6(2), 155-176. 
 
Hunter, DJ., 2016. Uncertainty in the Era of Precision Medicine. N Engl J Med 375(8), 711-3  
 
Hyman, DM., Puzanov, I., Subbiah, V. et al., 2015.  Vemurafenib in Multiple Nonmelanoma Cancers 
with BRAF V600 Mutations. N Engl J Med 373(8), 726-736.    
 
Korn, EL., Freidlin, B., 2017. Adaptive Clinical Trials: Advantages and Disadvantages of Various 
Adaptive Design Elements. J Natl Cancer Inst 109(6), djx013. 
 
Lassen, UN., Albert, CM., Kummar, S., Van Tilburg, CM., Dubois, SG., Geoerger, B., et al., 2018. 409O 
- Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing 
consistency in an age and tumor agnostic approach. Ann Oncol 29, viii133-viii48. 
 
Le Tourneau, C., Delord, JP., Gonçalves, A. et al., 2015. Molecularly targeted therapy based on 
tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, 
open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16(13), 1324-1334. 
A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
 
Martin-Liberal, J., Hierro, C., Ochoa de Olza, M., Rodon, J., 2017. Immuno-Oncology: The Third 
Paradigm in Early Drug Development. Target Oncol 12(2), 125-38. 
 
Massard, C., Michiels, S., Ferté, C., et al., 2017. High-Throughput Genomics and Clinical Outcome in 
Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov 7(6), 586-595.  
 
Menis, J., Hasan, B., Besse, B., 2014. New clinical research strategies in thoracic oncology: clinical 
trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. 
Eur Respir Rev 23(133), 367-378.  
 
MOtriColor. European Union’s Horizon 2020 research and innovation programme under grant 
agreement No 635342. http://www.motricolor.eu/project/ 
 
Mullard, A., 2015.  NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov 
14(8):513-515.  
 
Ocana, A., Amir, E., Vera-Badillo, F., et al., 2013. Phase III trials of targeted anticancer therapies: 
redesigning the concept. Clin Cancer Res 19(18), 4931-4940. 
 
Papadimitrakopoulou, V., Lee, JJ., Wistuba, II., et al., 2016. The BATTLE-2 Study: A Biomarker-
Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell 
Lung Cancer. J Clin Oncol 34(30), 3638-3647. 
 
Pemovska, T., Kontro, M., Yadav, B., et al., 2013. Individualized systems medicine strategy to tailor 
treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 3(12), 1416-
1429. 
 
Redig, AJ., Jänne, PA., 2015. Basket trials and the evolution of clinical trial design in an era of 
genomic medicine. J Clin Oncol 33(9), 975–977. 
 
Rodon, J., Saura, C., Dienstmann, R., et al., 2012.Molecular prescreening to select patient population 
in early clinical trials. Nat Rev Clin Oncol 9(6), 359-366. 
 
A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2019) © 2019 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
Weber, JS., Levit, LA., Adamson, PC., Bruinooge, SS., Burris, HA 3rd., Carducci, MA., Dicker AP., 
Gönen, M., Keefe, SM., Postow, MA., Thompson, MA., Waterhouse, DM., Weiner, SL., Schuchter, 
LM., 2017. Reaffirming and Clarifying the American Society of Clinical Oncology’s Policy Statement 
on the Critical Role of Phase I Trials in Cancer Research and Treatment. J Clin Oncol 35(2), 139–140 
 
Woodcock, J., LaVange, LM., 2017. Master Protocols to Study Multiple Therapies, Multiple Diseases, 
or Both. N Engl J Med 377(1), 62-70. 
 
Xiao, G., Ma, S., Minna, J., Xie, Y., 2014. Adaptive prediction model in prospective molecular 
signature-based clinical studies. Clin Cancer Res 20(3), 531-539. 
 
Yap, TA., Gerlinger, M., Futreal, PA., Pusztai, L., Swanton, C., 2012. Intratumor heterogeneity: seeing 
the wood for the trees. Sci Transl Med  4(127), 127ps110. 
 
 
Figure 1. Design of the Basket of Baskets (BoB) platform sponsored by Cancer Core Europe (CCE).  
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